https://www.selleckchem.com/pr....oducts/caerulein.htm
shold of 35 ml/m2 in risk stratification after AVR. BACKGROUND Transcatheter aortic valve replacement (TAVR) use is increasing in patients with longer life expectancy, yet robust data on the durability of transcatheter heart valves (THVs) are limited. Redo-TAVR may play a key strategy in treating patients in whom THVs fail. OBJECTIVES The authors sought to examine outcomes following redo-TAVR. METHODS The Redo-TAVR registry collected data on consecutive patients who underwent redo-TAVR at 37 centers. Patients were classified as probab
Like
Comment
Share
